Regulatory Authorities have Published a Report on COVID Vaccine Development
Global regulatory authorities have published a report describing the aligned positions on COVID-19 vaccine development, which were agreed upon by meeting participants of the second workshop on COVID-19 vaccine development.
Global regulatory authorities have published a report describing the aligned positions on COVID-19 vaccine development, which were agreed upon by meeting participants of the second workshop on COVID-19 vaccine development convened under the umbrella of the International Coalition of Medicines Regulatory Authorities.
According to a July 9, 2020 press release, the aligned positions incorporate two key topics, which are highlighted in the report. The topics are the need for data from laboratory, animal, and human studies so that Phase III clinical trials of a COVID-19 vaccine can be initiated, and considerations of study design for the Phase III clinical trials.
Emphasis was placed upon the requirement for Phase III clinical trials by the meeting participants, as these trials enroll thousands of people and should include those with underlying medical conditions so that relevant data can be generated. Additionally, there was agreement that the clinical studies should be designed with stringent success criteria to ensure there is convincing demonstration of efficacy.
More details are available on the European Medicines Agency’s website.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
